Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05170061 · ClinicalTrials.gov registry record · Phase 3
24 Hour Ambulatory Cardiac Oxygen Consumption
A Phase 3 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
NCT05170061: Completed Phase 3 study, sponsored by State University of New York at Buffalo.
NCT05170061 is a Phase 3 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 26 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05170061, a Phase 3 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
Study Summary
A randomized,double-blind, active controlled,15 week study to evaluate the effects of nebivolol and valsartan alone and in combination on 24-hour ambulatory cardiac work and variability of heart rate-mean central systolic pressure product.
Primary Outcome
ACRPP is the product of estimated aortic mean systolic pressure (mean aortic pressure estimated using a transfer function applied to brachial cuff blood pressure) during the systolic time interval adjusted for heart rate. Units are (mmHg\*beats/min).
Interventions
- DRUG Nebivolol
- DRUG Valsartan
- DRUG Nebivolol/valsartan combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
What the finished NCT05170061 record still lists
NCT05170061 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Nebivolol is the first listed.
NCT05170061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05170061 about?
NCT05170061 is a clinical study titled "24 Hour Ambulatory Cardiac Oxygen Consumption". A randomized,double-blind, active controlled,15 week study to evaluate the effects of nebivolol and valsartan alone and in combination on 24-hour ambulatory cardiac work and variability of heart rate-mean central systolic pressure product.
What is the current status of trial NCT05170061?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2013-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT05170061?
The interventions under investigation include: Nebivolol (DRUG), Valsartan (DRUG), Nebivolol/valsartan combination (DRUG).
Who is sponsoring clinical trial NCT05170061?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05170061's enrollment target sits among peer trials
26 1937th of 2000 higher than 60 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia